Galapagos: What deal should we be looking for now?

Having notified Galapagos that it is backing out of the deal on filgotinib to focus on its own JAK inhibitor, in our view AbbVie has opened the way for several pharmaceutical companies to take a closer look at filgotinib’s significant potential. With a phase III trial to start in H1 2016 and more than eight partners sitting around the negotiating table, it is now more relevant than ever to consider how Big Pharma might be valuing filgotinib.

For more information, please contact marketing@bryangarnier.com